Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | First-Line Chronic Lymphocytic Leukemia | US/EU | 2017
Market Outlook:
Despite advancements in the treatment landscape for first-line CLL with targeted agents such as Imbruvica, Zydelig, and Gazyva/Gazyvaro, it remains largely an incurable disease. Increasingly, drug developers are focusing on subsets of first-line CLL patients, such as elderly patients or those who harbor chromosome 17p deletions. The high unmet need for novel therapies with better efficacy and improved safety and tolerability profiles for the therapeutic management of first-line CLL presents notable commercial opportunity for drug developers.
Questions Answered:
- What are the treatment drivers and goals for first-line CLL? How do current therapies, such as Johnson & Johnson/Janssen/AbbVie’s Imbruvica, perform on these metrics?
- What attributes are key influencers, which have limited impact, and which are hidden opportunities?
- What are the prevailing areas of unmet need and opportunity in first-line CLL? Are late-phase emerging therapies targeting these areas?
- What trade-offs are surveyed hematological oncologists willing to make across different key clinical attributes and price, when considering hypothetical new treatment options in first-line CLL?
Production Description: Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
